ストックスクリーナーアプリを入手
1.63
1.21%
-0.02
アフターアワーズ：
1.59
-0.04
-2.45%
前日終値:
$1.65
開ける：
$1.62
24時間の取引高:
582.43K
Relative Volume:
0.38
時価総額：
$116.08M
収益：
$391.70K
当期純損益:
$-52.34M
株価収益率:
-2.1733
EPS:
-0.75
ネットキャッシュフロー:
$-45.92M
1週間 パフォーマンス:
+10.88%
1か月 パフォーマンス:
-9.94%
6か月 パフォーマンス:
+29.37%
1年 パフォーマンス:
+206.79%
1日の値動き範囲:
$1.59
$1.645
1週間の範囲:
$1.44
$1.67
52週間の値動き範囲:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
名前
Ovid Therapeutics Inc
セクター
電話
212-776-4381
住所
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.63 | 117.50M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-11 | 開始されました | Roth Capital | Buy |
| 2025-11-17 | 開始されました | Leerink Partners | Outperform |
| 2025-10-09 | 開始されました | Oppenheimer | Outperform |
| 2025-08-08 | 再開されました | B. Riley Securities | Buy |
| 2024-06-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 開始されました | B. Riley Securities | Buy |
| 2024-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-05 | 開始されました | Wedbush | Outperform |
| 2023-12-21 | 開始されました | BTIG Research | Buy |
| 2023-10-13 | 開始されました | Oppenheimer | Outperform |
| 2021-04-20 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-02 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-04-20 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Ovid Therapeutics Inc (OVID) 最新ニュース
Ovid Therapeutics (NASDAQ:OVID) Trading 7.3% HigherShould You Buy? - MarketBeat
Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Insider Sell: Is Ovid Therapeutics Inc still a buy after recent gainsTrade Risk Report & Stepwise Trade Execution Plans - baoquankhu1.vn
Aug Spikes: Is Ovid Therapeutics Inc still a buy after recent gainsMarket Activity Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Ovid Therapeutics (OVID) Sees 42.98% Increase Over the Past Week: Key Insights to Consider - Intellectia AI
ZCMD, ABCL, VOR, IXHL, OVID, BFRG Surge in After-Hours Trading Due to Clinical Progress and Recent Developments - Intellectia AI
Is Ovid Therapeutics Inc. being accumulated by smart moneyPortfolio Performance Summary & Daily Profit Focused Stock Screening - mfd.ru
Is Ovid Therapeutics (OVID) one of the best fast growing penny stocks to buy according to analysts? - MSN
Will Ovid Therapeutics Inc. announce a stock splitOptions Play & Safe Entry Point Alerts - mfd.ru
Is Ovid Therapeutics Inc. (1OT) stock a buy for dividend portfolios2025 Price Targets & Verified Swing Trading Watchlists - mfd.ru
What are Ovid Therapeutics Inc.’s earnings expectationsWeekly Trend Report & Low Volatility Stock Suggestions - mfd.ru
What makes Ovid Therapeutics Inc. stock attractive todayJuly 2025 Technicals & Safe Capital Allocation Plans - mfd.ru
IPO Launch: Is Ovid Therapeutics Inc being accumulated by smart moneyJuly 2025 Reactions & Low Drawdown Trading Strategies - baoquankhu1.vn
Aug Retail: Can Silicom Ltd. navigate macro headwindsM&A Rumor & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Rating of “Buy” from Analysts - Defense World
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Risk Hedge: Is Ovid Therapeutics Inc stock risky to hold nowJuly 2025 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Ovid Therapeutics $OVID Position Cut by TLS Advisors LLC - MarketBeat
Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? - Finviz
7 Best Fast Growing Penny Stocks to Buy According to Analysts - Insider Monkey
Both retail investors who control a good portion of Ovid Therapeutics Inc. (NASDAQ:OVID) along with institutions must be dismayed after last week's 11% decrease - simplywall.st
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha
Gains Report: Will Ionis Pharmaceuticals Inc benefit from sector rotation2025 Retail Activity & Growth Focused Investment Plans - baoquankhu1.vn
Does Ovid Therapeutics Inc. have declining or rising EPSWeekly Trend Report & Weekly Stock Breakout Alerts - mfd.ru
Why Ovid Therapeutics Inc. (1OT) stock stays on top picksTrading Volume Trends & Use Time as Your Investing Ally - bollywoodhelpline.com
Investment Recap: Will Ovid Therapeutics Inc announce a stock splitEntry Point & Expert Curated Trade Ideas - baoquankhu1.vn
What is the target price for Ovid Therapeutics Inc. stockQuarterly Trade Summary & Weekly Top Gainers Alerts - bollywoodhelpline.com
Sectors Review: Is Ovid Therapeutics Inc stock risky to hold now2025 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Risk Hedge: Will BMBL benefit from AI trends2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
Why is Ovid Therapeutics Inc stock going upEarnings Risk Summary & Low Drawdown Trading Techniques - baoquankhu1.vn
Can Ovid Therapeutics Inc. (1OT) stock sustain breakout momentumJuly 2025 Summary & Fast Exit/Entry Strategy Plans - bollywoodhelpline.com
Ovid Therapeutics (NASDAQ:OVID) Downgraded to Sell Rating by Wall Street Zen - Defense World
Aug Analyst Calls: What risks investors should watch in Ovid Therapeutics Inc stockWeekly Trading Summary & Verified Technical Signals - Bộ Nội Vụ
Market Review: Does Ovid Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
How Ovid Therapeutics Inc. stock performs in weak economyMarket Growth Review & Accurate Entry/Exit Alerts - Улправда
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
During J. P. Morgan Healthcare Week, Biotech Showcase™ Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma Partners and Media - TradingView
Published on: 2026-01-09 08:22:12 - Улправда
Is Ovid Therapeutics Inc. (1OT) stock safe for risk averse investorsWeekly Trade Report & Real-Time Volume Trigger Notifications - Улправда
Why hedge funds are buying Ovid Therapeutics Inc. stockQuarterly Trade Summary & Technical Analysis for Trade Confirmation - Улправда
Can Ovid Therapeutics Inc. stock hit record highs againQuarterly Investment Review & Weekly Consistent Profit Watchlists - Улправда
Will Ovid Therapeutics Inc. stock benefit from upcoming earnings reports2025 Buyback Activity & Reliable Price Action Trade Plans - Улправда
Aug Spikes: Can Ovid Therapeutics Inc 1OT stock sustain breakout momentumEarnings Overview Report & Safe Capital Growth Stock Tips - Bộ Nội Vụ
How Ovid Therapeutics Inc. stock reacts to oil prices2026 world cup usa national team qualification goalkeepers low block defense knockout prediction statistical analysis - ulpravda.ru
Ovid Therapeutics (OVID) Price Target Increased by 22.06% to 4.23 - MSN
Is Ovid Therapeutics Inc. stock positioned well for digital economy2026 world cup usa national team round of 32 defensive leaders low block defense group prediction preview - ulpravda.ru
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Ovid Therapeutics is a buy, this analyst says - Cantech Letter
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Hold" - MarketBeat
Ovid Therapeutics (STU:1OT) EV-to-FCF : -2.91 (As of Dec. 26, 2025) - GuruFocus
Ovid Therapeutics Inc (OVID) 財務データ
収益
当期純利益
現金流量
EPS
1.18%
0.45%
大文字化:
|
ボリューム (24 時間):